Anticancer Research

• 

  Publication Venue For

  • Hospital Volume Threshold for the Treatment of Retroperitoneal Sarcoma..  39:2007-2014. 2019
  • Transperitoneal Versus Extraperitoneal Laparoscopic Lymphadenectomy for Gynecological Malignancies: A Systematic Review and Meta-analysis..  38:4677-4681. 2018
  • Chemotherapy or Combined Modality Therapy for Early-stage Hodgkin Lymphoma..  38:2875-2881. 2018
  • Update on Surgical Management of Small Bowel Neuroendocrine Tumors..  38:1267-1278. 2018
  • Neuroendocrine Neoplasms of the Appendix: A Review of the Literature..  38:601-611. 2018
  • The "Yin and Yang" of Platelet-rich Plasma in Breast Reconstruction After Mastectomy or Lumpectomy for Breast Cancer..  37:6557-6562. 2017
  • Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas..  37:2185-2194. 2017
  • Comprehensive Surgical Treatment as the Mainstay of Management in Retroperitoneal Sarcomas: Retrospective Study from Two Non-sarcoma Specialist Centers..  37:2025-2031. 2017
  • Non-Whipple Operations in the Management of Benign, Premalignant and Early Cancerous Duodenal Lesions..  37:1443-1452. 2017
  • De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-center Experience..  37:773-779. 2017
  • Plasma Metabolites and Risk of Radiation-induced Esophagitis: A Secondary Analysis from a Prospective Study..  37:719-725. 2017
  • Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer..  37:35-46. 2017
  • Minimally Invasive Lymphadenectomy in Uterine Cervical Cancer: A Systematic Review..  37:335-342. 2017
  • Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes..  37:9-14. 2017
  • Chest Wall Deformity in the Radiation Oncology Clinic..  36:5295-5300. 2016
  • The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma..  35:2465-2474. 2015
  • Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era..  34:2405-2411. 2014
  • c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival..  33:3241-3245. 2013
  • Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer..  32:4963-4969. 2012
  • A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors..  32:1689-1696. 2012
  • Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide..  31:4537-4543. 2011
  • Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer..  31:1417-1420. 2011
  • A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer..  31:255-261. 2011
  • Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models..  30:5037-5042. 2010
  • A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors..  30:1251-1256. 2010
  • Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors..  29:5149-5153. 2009
  • Effect of a metalloporphyrin antioxidant (MnTE-2-PyP) on the response of a mouse prostate cancer model to radiation..  29:107-118. 2009
  • GENETIC PROFILING IN TUMOR XENOGRAFTS FROM PAEDIATRIC GLIOMAS BY EXPRESSION AND HIGH RESOLUTION COMPARATIVE GENOMIC HYBRIDISATION MICROARRAYS.  28:3341-3341. 2008
  • MALIGNANT GROWTH IN THE BONE MARROW CREATES ABNORMAL HEMATOPOIETIC PROGENITOR CELL NICHES.  28:3555-3555. 2008
  • Photodynamic therapy of Barrett's esophagus: ablation of Barrett's mucosa and reduction in p53 protein expression after treatment..  28:485-489. 2008
  • Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate..  27:3941-3946. 2007
  • Radiolabelling of glucose-Tyr³ -octreotate with ¹²⁵ I and analysis of its metabolism in rats: Comparison with radiolabelled DOTA-Tyr³ -octreotate.  27:3941-3946. 2007
  • Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model.  27:3101-3109. 2007
  • Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model..  27:3101-3109. 2007
  • Gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients with advanced biliary tree cancers: a pilot study..  26:771-775. 2006
  • Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line..  25:1-8. 2005
  • p63 expression profile in normal and malignant prostate epithelial cells..  22:3819-3825. 2002
  • Heat shock protein 70 (HSP70) does not prevent the inhibition of cell growth in DU-145 cells treated with TGF-beta1..  21:3341-3347. 2001
  • Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.  21:1241-1246. 2001
  • Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model..  21:1713-1722. 2001
  • Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer..  21:1241-1246. 2001
  • Complex response of breast epithelial cell lines to topoisomerase inhibitors..  18:2919-2932. 1998
  • Molecular characterization of the human delta opioid receptor in lung cancer..  18:1787-1792. 1998
  • Molecular characterization of the human δ opioid receptor in lung cancer.  18:1787-1792. 1998
  • Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer..  17:795-801. 1997
  • Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer.  17:795-801. 1997
  • Growth inhibition of a human lung adenocarcinoma cell line by genetic complementation with chromosome 11.  17:3243-3251. 1997
  • Discrimination between tumour and normal cells by staining with 3,4,5,6,16,17-hexadehydro-16-(methoxycarbonyl)-19α-methyl-20α -oxayohimbanium: The uracil ring as a target for the specific interaction between RNA(s) and the fluorescent probe.  16:1881-1886. 1996
  • Tumor oxygenation: a matter of supply and demand..  16:741-749. 1996
  • The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors..  16:375-380. 1996
  • Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours.  15:2495-2499. 1995
  • Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours..  15:2495-2499. 1995
  • Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells..  15:1339-1342. 1995
  • Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines..  14:247-251. 1994
  • p53 gene mutation spectrum in human unknown primary tumors..  13:1619-1623. 1993
  • ANTINEOPLASTIC ACTIVITY OF BORON-CONTAINING THYMIDINE NUCLEOSIDES IN TMOLT(3) LEUKEMIC-CELLS.  12:1091-1098. 1992
  • THE SYNTHESIS AND ANTINEOPLASTIC ACTIVITY OF 2'-DEOXY-NUCLEOSIDE-CYANOBORANES IN MURINE AND HUMAN CULTURE CELLS.  12:335-343. 1992
  • DNA interstrand crosslinking and strand break repair in human glioma cell lines of varying [1,3-bis(2-chloroethyl)-1-nitrosourea] resistance..  10:677-682. 1990
  • Effect of epidermal growth factor on ornithine decarboxylase activity in A431 cells..  9:209-213. 1989
  • Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis..  4:133-140. 1984
  • IMAGE-GUIDED ROBOTIC RADIOSURGERY TREATMENT AS SALVAGE THERAPY FOR LOCALLY RECURRENT PROSTATE CANCER 2015
  • IMPACT OF [C-11] CHOLINE PET/CT IN THE CLINICAL MANAGEMENT AND RADIATION TREATMENT PLANNING OF RECURRENT PROSTATE CANCER FOLLOWING EBRT 2015
  • ROBOTIC IMAGE-GUIDED STEREOTACTIC RADIOTHERAPY FOR ISOLATED LYMPH NODE PROSTATE METASTASES 2015
  • STEREOTACTIC BODY RADIOTHERAPY FOR PROSTATE CANCER 2015
  • PROSTATE HYPOFRACTIONATED STEREOTACTIC ABLATIVE BODY RADIOTHERAPY: DISEASE CONTROL AND QUALITY OF LIFE AT 6 YEARS 2014
  • STEREOTACTIC BODY RADIATION THERAPY IN THE TREATMENT OF OLIGOMETASTATIC PROSTATE CANCER: DEFFERING ANDROGEN DEPRIVATION THERAPY 2014